Navigation Links
Lpath Withdraws From Pfizer's Process to Assign iSONEP Rights
Date:12/12/2013

cautions you that the statements included in this press release that are not a description of historical facts are forward-looking statements. These include statements regarding Pfizer's plans to divest its exclusive option for a worldwide license to develop and commercialize iSONEP, third party interest in acquiring the exclusive option from Pfizer, and Pfizer's ability to successfully complete a sale of the exclusive option.  Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in the Company's business, including, without limitation: the results of the Company's preclinical studies and clinical trials may not support further clinical development and/or the commercialization of its drug candidates; the Company may not successfully complete additional clinical trials for its product candidates on a timely basis, or at all; the Company may fail to obtain required governmental approvals for any its drug candidates; the Company may not be successful in maintaining its commercial relationship with Pfizer Inc. or any third party who acquires Pfizer's exclusive option to iSONEP; and the Company may not be able to secure the funds necessary to support its preclinical-development and clinical-development plans. More detailed information about the risk factors and uncertainties that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (the "SEC"), including its Annual Report on Form 10-K, its Quarterly Reports on Form 10-Q, and its other filings with the SEC. These documents may be read free of charge on the SEC's website at www.sec.gov. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and the Company undertakes no obl
'/>"/>
SOURCE Lpath, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Gen-Probe Withdraws from Previously Announced Investor Presentations
2. Matrixx Initiatives Withdraws Acquisition Offer for ProPhase Labs
3. GenVec Board Restructures Operations and Withdraws Plan of Dissolution
4. TeraDiscoveries to Use its Inverse Design Software Running on Windows Azure to Advance Its Computational Drug Discovery Process
5. Haemonetics Signs Definitive Agreement to Acquire Pall Corporations Blood Collection, Filtration and Processing Product Lines For $551 Million
6. I.V. Clinical Integration Helps Deliver Safety, Efficiency And Financial Benefits; Hospira Shares Snapshot Of Results, Process
7. ZyDoc Selects Health Fidelitys REVEAL™ Natural Language Processing (NLP) Platform to Accelerate Time to Value for its MediSapien Web Services
8. PendoTECH Single Use Process Sensors Reduce The Environmental Impact Of Critical Bioprocess Operations
9. Physician Details Problems with Medicare Approval Process for Power Wheelchairs
10. GP Strategies Partners with ATR, Inc. to Provide Advanced Procedure Improvement Technology Solutions to the Process Industry
11. International Isotopes Inc. Announces Nuclear Regulatory Commission Approval Of The Final Environmental Impact Statement For The Planned Depleted Uranium De-Conversion And Fluorine Extraction Processing Facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... Research and Markets ( ... "Investigation Report on China,s Tobramycin Market, 2010-2019" report ... antibiotic whose eye drop and ointment are the most ... or inflammation caused by eye infection. Currently, dozens of ... to produce tobramycin, among which the Top 5 are ...
(Date:8/28/2015)... Research and Markets ( ... "Investigation Report on China,s Insulin Aspart Market, ... Developed by Novo Nordisk, insulin aspart (under the ... for the treatment of diabetes. Compared with human ... analog, starts working fast and reports higher peak ...
(Date:8/28/2015)... 28, 2015  IP Shakti, LLC, today announced that it ... Logo - http://photos.prnewswire.com/prnh/20150827/261551LOGO ... new corporate identity signifies our transformation into a company focused ... platform for patent claim validity." ... proprietary AIA Shield™ platform, the Company commenced a corporate re-branding ...
Breaking Medicine Technology:Investigation Report on China's Tobramycin Market, 2015-2019 2China Insulin Aspart Market Report 2010-2019 - Developed by Novo Nordisk 2IP Shakti, LLC Changes Company Name to Prediqtus, LLC 2
... RATON, Fla., Sept. 15 Watermark Medical , ... the sleep-disordered breathing market, has expanded the market reach ... strategic alliances with three leading sleep solution providers in ... SleepQuest , a national provider of comprehensive sleep apnea ...
... Sept. 15 ViroPharma Incorporated (Nasdaq: VPHM ... Phase 1 study of VP20621 (non-toxigenic Clostridium difficile ... Clostridium difficile infections (CDI), a common and dangerous ... of antibiotic medications.  VP20621 contains the spores of a ...
Cached Medicine Technology:Three Leading Sleep Solution Providers Choose Watermark Medical's Web-Enabled Home Sleep Testing Solutions 2Three Leading Sleep Solution Providers Choose Watermark Medical's Web-Enabled Home Sleep Testing Solutions 3Three Leading Sleep Solution Providers Choose Watermark Medical's Web-Enabled Home Sleep Testing Solutions 4ViroPharma Announces Presentation of Data from Non-Toxigenic Clostridium difficile (VP20621) Phase 1 Study 2ViroPharma Announces Presentation of Data from Non-Toxigenic Clostridium difficile (VP20621) Phase 1 Study 3ViroPharma Announces Presentation of Data from Non-Toxigenic Clostridium difficile (VP20621) Phase 1 Study 4ViroPharma Announces Presentation of Data from Non-Toxigenic Clostridium difficile (VP20621) Phase 1 Study 5ViroPharma Announces Presentation of Data from Non-Toxigenic Clostridium difficile (VP20621) Phase 1 Study 6
(Date:8/28/2015)... ... August 28, 2015 , ... As reported by Medical Daily ... FDA clearance for results that last for two years, the longest of any cellulite ... who are looking for a long-lasting, effective solution for their cellulite, according to Dr. ...
(Date:8/28/2015)... ... August 28, 2015 , ... Saint ... grade protein with zero fat, carbs, sugar, gluten, lactose or caffeine in a ... for the 2015 SupplySide CPG Editor’s Choice Awards. , Five consumer packaged goods ...
(Date:8/28/2015)... ... August 28, 2015 , ... Medical Solutions, one of the nation’s largest ... Work in Healthcare by Modern Healthcare and will be honored at an awards ... eighth year, the Best Places to Work in Healthcare program recognizes outstanding employers in ...
(Date:8/28/2015)... ... August 28, 2015 , ... SmartPractice Calendars afford ... with practice contact information and logos, Calendars stand alone as functional brand-building ... into seasonal mailings, thank you and welcome communications, and to complement statements and ...
(Date:8/28/2015)... ... August 28, 2015 , ... ... collaboration with coffee connoisseur and Emmy-nominated actress, Sofia Vergara, and unveil the Ninja® ... Thermal Flavor Extraction™ technology, which delivers a variety of sizes and styles while ...
Breaking Medicine News(10 mins):Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 3Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 2Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 3Health News:Medical Solutions Recognized as One of 2015 Best Places to Work in Healthcare 2Health News:Medical Solutions Recognized as One of 2015 Best Places to Work in Healthcare 3Health News:SmartPractice® Introduces 2016 Calendars for Dental Practice Giveaways 2Health News:Sofia Vergara Partners With SharkNinja® To Launch The Ninja Coffee Bar™ 2Health News:Sofia Vergara Partners With SharkNinja® To Launch The Ninja Coffee Bar™ 3
... may potentially play a role in the maintenance of ... a recent issue of Nutrition in Clinical Care. The ... on risk factors for heart disease. Several studies suggest ... and blood pressure. It may also help keep blood ...
... doses of painkillers to ease the agony of terminally ... have criticized the practice, comparing it to euthanasia, but ... receiving higher doses of drugs such as morphine live ... , ,In research published in The Lancet medical journal, ...
... children with autism. Antibiotcs seem to treat or prevent the ... every 150 children is affected by autism. Currently there are ... Hospital in Chicago found that a subset of patients with ... can be helped by antibiotic vancomycin. ,Interestingly the ...
... The discovery of the gene associated with the inherited form ... of Columbia University and James A. Knowles of the Columbia ... study, funded in part by the National Heart, Lung, and ... in the September issue of the American Journal of Human ...
... when given to children with diarrhea caused by ... increased risk of developing a serious condition known ... website of The New England Journal of Medicine ... children after a gastrointestinal infection, begins with vomiting ...
... and Blood Institute (NHLBI) and the National High Blood ... to treat Hypertension.,Control of systolic blood pressure is as ... a crucial message for health care providers, patients, and ... systolic blood pressure to less than 140 mm Hg ...
Cached Medicine News:
The Emit 2000 Digoxin Calibrators are intended for use with the Emit 2000 Digoxin Assay....
... The Newmarket Laboratories RPR kits ... mixture of lipid antigens, which will ... serum or plasma. The particles are ... to eliminate non - specific reactions. ...
... a quality assurance reagent in assays detecting ... (TOXO IgG and TOXO IgM), IgG and ... and rubella IgM), IgG and IgM antibodies ... and IgG antibodies to herpes simplex virus ...
... The Diamedix Immunosimplicity (Is) Rubella ... procedure,intended for the qualitative and quantitative ... test can be performed either manually ... Automated EIA Processor. The results are ...
Medicine Products: